Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
R Donald HarveyPhase 1 Clinical Trials Section, Winship Cancer Institute of Emory University, Atlanta, GA, USAAbstract: Carfilzomib, a selective proteasome inhibitor approved in the USA in 2012, is a single agent for relapsed and refractory multiple myeloma. Carfilzomib is administered as a 2&n...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2014
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/e61e73945e8e499f9a1d996fbc7afd8c |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|